Latest

Learn how lung cancer MRD ctDNA testing detects molecular residual disease, what positive and negative results mean, how it can precede recurrence on scans, and why treatment decisions still require clinical context.

Minimal Residual Disease ctDNA Test for Lung Cancer: Recurrence Monitoring, MRD, and Tumor DNA

Learn what MSI testing means in lung cancer, how MSI-H, MSS, dMMR, and pMMR results differ, how NGS, PCR, and IHC are used, and why this rare biomarker can matter for immunotherapy and hereditary evaluation.

MSI Test for Lung Cancer: Microsatellite Instability, Mismatch Repair, and Result Meaning

Learn how Napsin A IHC supports lung adenocarcinoma diagnosis, what positive granular cytoplasmic staining means, why negative results do not exclude lung cancer, and when other tumor origins must be considered.

Napsin A IHC Test for Lung Cancer: Adenocarcinoma Marker, Tumor Origin, and Positive...

Non-Small Cell Lung Cancer Biomarker Test: Driver Mutations, PD-L1, and Molecular Profile

Learn what an NSE blood test means in small cell lung cancer, why levels can be high, how hemolysis causes false elevations, and how serial NSE trends may support treatment and recurrence monitoring.

NSE Test for Lung Cancer: Small Cell Lung Cancer Marker, High Levels, and...

Understand NTRK fusion testing in lung cancer, including tumor-agnostic meaning, RNA NGS, pan-TRK IHC, positive results, negative-result limits, and next steps.

NTRK Fusion Test for Lung Cancer: Gene Fusion, Tumor-Agnostic Marker, and Molecular Meaning

Diagnostics

Home Diagnostics Page 3

Learn how CALR mutation testing helps diagnose essential thrombocythemia and myelofibrosis, what type 1 and type 2 variants mean, and how results affect risk.

CALR Mutation Test: Essential Thrombocythemia, Myelofibrosis, Platelets, and Mutation Meaning

Learn how CCND1/IGH FISH detects t(11;14) in mantle cell lymphoma, what positive and negative results mean, and how cyclin D1 and SOX11 support diagnosis.

CCND1/IGH Fusion Test: Mantle Cell Lymphoma, Cyclin D1, and FISH Result

Learn what a CD19 test shows in B-cell leukemia and lymphoma, how positive staining is interpreted, and why CD19 matters before and after CAR-T therapy.

CD19 Test: B-Cell Leukemia, Lymphoma, CAR-T Marker, and Positive Staining

Learn what CD20-positive staining means in B-cell lymphoma, how flow cytometry and IHC differ, and why CD20 expression can change after targeted therapy.

CD20 Test: B-Cell Lymphoma Marker, B-Cell Lineage, and Positive Staining

Learn what a CD22 test shows in B-cell leukemia and lymphoma, what positive or dim staining means, and how CD22 can affect diagnosis, treatment, and MRD testing.

CD22 Test: B-Cell Leukemia, Lymphoma Marker, and Positive Staining

Understand what a CD30 test means in Hodgkin and T-cell lymphomas, how positive staining is interpreted, and when CD30 expression may affect diagnosis and targeted therapy.

CD30 Test: Hodgkin Lymphoma, T-Cell Lymphoma, Positive Staining, and Marker Meaning

Learn what a CD33 test means in AML, how myeloid blast positivity is interpreted, and how CD33 expression can affect leukemia diagnosis, targeted treatment, and MRD follow-up.

CD33 Test: AML Marker, Myeloid Blasts, and Positive Staining

Understand what a CD34 test means in leukemia and stem cell testing, how positive blast staining is interpreted, and why CD34 alone does not diagnose acute leukemia.

CD34 Test: Leukemia Blast Marker, Stem Cell Marker, and Positive Staining

Learn what a CD38 test means in multiple myeloma and CLL, how positive staining is interpreted, and how anti-CD38 therapy can change flow cytometry and MRD testing.

CD38 Test: Myeloma Marker, CLL Marker, and Positive Staining

Understand what a CD138 test shows in bone marrow, what positive plasma-cell staining means, and how CD138 helps assess multiple myeloma and related disorders.

CD138 Test: Plasma Cell Marker, Myeloma, and Bone Marrow Assessment

Understand CLL FISH results for del(17p), del(11q), trisomy 12, and del(13q), including what they mean for TP53 risk, prognosis, repeat testing, and treatment planning.

Chronic Lymphocytic Leukemia (CLL) FISH Panel: del17p, del11q, Trisomy 12, and...

Understand CLL IGHV mutation testing, the 98% mutated/unmutated cutoff, what IGHV means for prognosis, and how it fits with TP53, FISH, and modern treatment decisions.

CLL IGHV Mutation Test: Prognosis, Mutation Status, and Treatment Risk

Learn how the ClonoSEQ MRD test tracks residual leukemia, lymphoma, and myeloma, what positive or undetectable results mean, and why sample sensitivity matters.

ClonoSEQ Test: MRD Monitoring in Leukemia, Lymphoma, Myeloma, and Result Meaning

Understand CXCR4 mutation testing in Waldenstrom macroglobulinemia, including positive and negative results, common variants, prognosis, BTK inhibitor response, and test limits.

CXCR4 Mutation Test: Waldenstrom Macroglobulinemia, Mutation Status, and Disease Meaning

Learn what a cyclin D1 test means in mantle cell lymphoma, including positive nuclear staining, CCND1 rearrangements, negative results, SOX11, FISH, and key diagnostic pitfalls.

Cyclin D1 Test for Mantle Cell Lymphoma: Positive Staining and Diagnostic...

Understand DNMT3A mutation test results in AML and clonal hematopoiesis, including R882 variants, VAF, CHIP and CCUS, prognosis, remission persistence, and follow-up meaning.

DNMT3A Mutation Test: AML, Clonal Hematopoiesis, Myeloid Neoplasms, and Mutation Meaning

Learn how a double-hit lymphoma FISH panel interprets MYC, BCL2, and BCL6 rearrangements, including double-hit, triple-hit, double-expressor, and modern classification meaning.

Double-Hit Lymphoma FISH Panel: MYC, BCL2, BCL6, and Rearrangement Status

Understand FLT3 mutation test results in AML, including ITD vs TKD, ELN 2022 risk, allelic ratio, VAF, targeted therapy, MRD, relapse retesting, and prognosis.

FLT3 Mutation Test: AML Risk, Mutation Status, Prognosis, and Result Meaning

Learn how hematologic cancer biomarker panels use flow cytometry, IHC, FISH, PCR, NGS, and protein studies to diagnose and classify leukemia, lymphoma, and myeloma.

Hematologic Cancer Biomarker Panel: Leukemia, Lymphoma, Myeloma Markers, and Diagnosis

Understand what an IDH1 mutation test means in AML, including R132 variants, positive and negative results, VAF, prognosis, targeted IDH1 therapy, and follow-up.

IDH1 Mutation Test for AML: Mutation Status, Molecular Result, and AML...

1 234...92 Page 3 of 92